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A B S T R A C T
Background
Refractory peptic ulcers are ulcers in the stomach or duodenum that do not heal after eight to 12 weeks of medical treatment or those
that are associated with complications despite medical treatment. Recurrent peptic ulcers are peptic ulcers that recur after healing of
the ulcer. Given the number of deaths due to peptic ulcer-related complications and the long-term complications of medical treatment
(increased incidence of fracture), it is unclear whether medical or surgical intervention is the better treatment option in people with
recurrent or refractory peptic ulcers.
Objectives
To assess the benefits and harms of medical versus surgical treatment for people with recurrent or refractory peptic ulcer.
Search methods
We searched the specialised register of the Cochrane Upper GI and Pancreatic Diseases group, the Cochrane Central Register of
Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and trials registers
until September 2015 to identify randomised trials and non-randomised studies, using search strategies. We also searched the references
of included studies to identify further studies.
Selection criteria
We considered randomised controlled trials and non-randomised studies comparing medical treatment with surgical treatment in
people with refractory or recurrent peptic ulcer, irrespective of language, blinding, or publication status for inclusion in the review.
Data collection and analysis
Two review authors independently identified trials and extracted data. We planned to calculate the risk ratio, mean difference, standard-
ised mean difference, or hazard ratio with 95% confidence intervals using both fixed-effect and random-effects models with Review
Manager 5 based on intention-to-treat analysis.
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Main results
We included only one non-randomised study published 30 years ago in the review. This study included 77 participants who had
gastric ulcer and in whom medical therapy (histamine H2 receptor blockers, antacids, and diet) had failed after an average duration of
treatment of 29 months. The authors do not state whether these were recurrent or refractory ulcers. It appears that the participants did
not have previous complications such as bleeding or perforation. Of the 77 included participants, 37 participants continued to have
medical therapy while 40 participants received surgical therapy (antrectomy with or without vagotomy; subtotal gastrectomy with or
without vagotomy; vagotomy; pyloroplasty and suture of the ulcer; suture or closure of ulcer without vagotomy or excision of the ulcer;
proximal gastric or parietal cell vagotomy alone; suture or closure of the ulcer with proximal gastric or parietal cell vagotomy). Whether
to use medical or surgical treatment was determined by participant’s or treating physician’s preference.
The study authors reported that two participants in the medical treatment group (2 out of 37; 5.4%) had gastric cancer, which was
identified by repeated biopsy. They did not report the proportion of participants who had gastric cancer in the surgical treatment
group. They also did not report the implications of the delayed diagnosis of gastric cancer in the medical treatment group. They did
not report any other outcomes of interest for this review (that is health-related quality of life (using any validated scale), adverse events
and serious adverse events, peptic ulcer bleeding, peptic ulcer perforation, abdominal pain, and long-term mortality).
Authors’ conclusions
We found no studies that provide the relative benefits and harms of medical versus surgical treatment for recurrent or refractory peptic
ulcers. Studies that evaluate the natural history of recurrent and refractory peptic ulcers are urgently required to determine whether
randomised controlled trials comparing medical versus surgical management in patients with recurrent or refractory peptic ulcers or
both are necessary. Such studies will also provide information for the design of such randomised controlled trials. A minimum follow-
up of two to three years will allow the calculation of the incidence of complications and gastric cancer (in gastric ulcers only) in recurrent
and refractory peptic ulcers. In addition to complications related to treatment and disease, health-related quality of life and loss of
productivity should also be measured.
P L A I N L A N G U A G E S U M M A R Y
Medical or operative treatment for ulcers in the stomach and upper small intestine resistant to medical treatment
Review question
In people who have stomach or upper small intestinal ulcers (peptic ulcers) that do not heal after eight to 12 weeks of medical treatment
(refractory peptic ulcers) or comes back after healing (recurrent peptic ulcers), is medical or surgical treatment better?
Background
Approximately 1 in 100 to 1 in 800 people have peptic ulcers. The major causes of peptic ulcer are Helicobacter pylori infection, non-
steroidal anti-inflammatory drug (NSAID) use, and smoking. People who have peptic ulcer have upper abdominal pain, which is
sometimes accompanied by dyspepsia (that is fullness, bloating, loss of appetite after eating a small amount of food, or nausea). The
most serious complications of peptic ulcers are bleeding from the ulcer and perforation of the peptic ulcer, which results in stomach
or upper small intestinal contents or both leaking into the tummy. About 1 in 10 people with bleeding peptic ulcer and 1 in 4 people
with perforated peptic ulcer die. Peptic ulcers cause approximately 3000 to 4500 deaths per year in the US.
Currently, medical management, usually with a group of drugs called proton pump inhibitors (such as omeprazole and lansoprazole), is
the mainstay treatment for uncomplicated peptic ulcers. Recently concerns have arisen about the risk of fractures with long-term use of
proton pump inhibitors. The alternative to medical treatment for refractory and recurrent peptic ulcer is surgical treatment to decrease
the acid secretion in the stomach with the goal of curing the peptic ulcer. It is not known whether medical or surgical management
is a better option for people with a refractory or recurrent peptic ulcer. We attempted to resolve this issue by searching the medical
literature for studies comparing medical and surgical treatment in people with refractory or recurrent peptic ulcers.
Study characteristics
We found no randomised controlled trials, and identified only one non-randomised study published 30 years ago, on this topic. This
study included 77 participants who had stomach ulcer and in whom medical therapy had failed after an average treatment duration
of 29 months. Medical therapy included histamine H2 receptor blockers (medicines that block the action of the chemical histamine,
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resulting in a decreased production of stomach acid, such as ranitidine), antacids, and diet. It must be highlighted that this form of
medical treatment is not considered to be as effective as treatment with proton pump inhibitors. The authors do not state whether
these were recurrent or refractory ulcers. Of the 77 included participants, 37 participants continued to have medical therapy, while
40 participants received surgical therapy. Whether to use medical or surgical treatment was determined by participant’s or treating
physician’s preference. The evidence is current to September 2015.
Key results
The study authors reported that two participants in the medical treatment group (5%) had stomach cancer, which was identified after
repeated examinations using a camera to look inside the body (an endoscope), in this case, the stomach and small intestine. They
did not report the percentage of participants who had stomach cancer in the surgical treatment group. They also did not report the
implications of the delayed diagnosis of stomach cancer in the medical treatment group. They did not report any other outcomes of
interest (measures by which one treatment can be considered better than another) for this review (that is health-related quality of life,
treatment-related complications, peptic ulcer-related complications, abdominal pain, and long-term deaths). There is thus no study
that provides the relative benefits and harms of medical versus surgical treatment for recurrent or refractory peptic ulcers. Studies on
this topic are urgently required.
Quality of the evidence
Since the only study that compared medical and surgical treatment in people with refractory or recurrent ulcers did not report any of
the outcomes in a sufficiently detailed manner, we were not able to assess the quality of evidence in a formal way.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Medical treatments compared with surgery for refractory or recurrent peptic ulcer
Patient or population: adults with refractory or recurrent peptic ulcer
Settings: primary care (medical treatment) and secondary care (surgical treatment)
Intervention: medical treatment
Comparison: surgical treatment
We included only one non-randomised study published 30 years ago in this review. This study included 77 participants, of whom 37
participants continued to have medical therapy, while 40 participants received surgical therapy after an average duration of medical
treatment with histamine H2 receptor blockers, antacids, and diet. Whether to use medical or surgical treatment was determined by
participant’s or treating physician’s preference
The study authors reported that two participants in the medical treatment group (2 out of 37; 5.4%) had gastric cancer, which was
identified by repeated biopsy. They did not report the proportion of participants who had gastric cancer in the surgical treatment group.
They also did not report the implications of the delayed diagnosis of gastric cancer in the medical treatment group. They did not report
any other outcomes of interest for this review (that is health-related quality of life (using any validated scale), adverse events and
serious adverse events, peptic ulcer bleeding, peptic ulcer perforation, abdominal pain, and long-term mortality). We therefore could
not derive the quality of the evidence
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Description of the condition
See Appendix 1 for a glossary of terms used in this section.
Peptic ulcer includes gastric and duodenal ulcers (Malfertheiner
2009). Gastric and duodenal ulcers involve defects in the mucosal
lining of the stomach and duodenum, respectively. The one-year-
period prevalence of physician-diagnosed peptic ulcer disease (that
is had peptic ulcer in a one-year period) varies between 0.12% and
1.5% (Sung 2009). The annual incidence of physician-diagnosed
peptic ulcer disease is between 0.14% and 0.19% (Sung 2009).
There has been a steady decline in the incidence and prevalence of
peptic ulcer disease (Sung 2009). Helicobacter pylori (H. pylori) in-
fection, non-steroidal anti-inflammatory drug (NSAID) use, and
smoking are the major risk factors for peptic ulcer (Huang 2002;
Kurata 1997). H. pylori induces and maintains inflammation of
the gastricmucosa leading to gastric ulcers (Peek 1997). It increases
acid secretion by increasing gastrin secretion (which, in turn, in-
creases gastric acid secretion) and increases the acid secretion re-
sponse of the stomach to gastrin (Malfertheiner 2011; Peek 1997).
In addition, H. pylori also inhibits the inhibitory mechanisms that
regulate the acid secretion, resulting in increased acid secretion
(Malfertheiner 2011). Increased acid in the duodenum causes gas-
tric metaplasia (replacement of duodenal epithelium with gastric
epithelium), which is the defensive reaction of the body. However,
gastric metaplasia predisposes infection of the duodenum with H.
pylori leading to duodenal ulcers (Malfertheiner 2011). Increasing
age and male gender are associated with increased incidence of
peptic ulcer (Lin 2011; Malmi 2014).
The major symptom of uncomplicated peptic ulcer is upper ab-
dominal pain, which may be associated with dyspeptic symptoms
such as fullness, bloating, early satiety, and nausea (Malfertheiner
2011). In people with a duodenal ulcer, upper abdominal pain typ-
ically occurs on an empty stomach or during the night and is usu-
ally relieved by eating or by taking antacids (Malfertheiner 2011).
Bleeding and perforation are the two major common complica-
tions of peptic ulcers (Hermansson 2009; Hernandez-Diaz 2013;
Malmi 2014; Post 2006). The incidence rate of complications
in people without uncomplicated peptic ulcers is 4.6 per 1000
person-years (Hernandez-Diaz 2013). The incidence of bleeding
peptic ulcer in the general population varies between 0.27 and
1.06 per 1000 person-years, while that of perforated peptic ulcer
in the general population is 0.03 to 0.30 per 1000 person-years
(Lin 2011). H. pylori infection is a major risk factor for the de-
velopment of complications (Hernandez-Diaz 2013). While the
incidence of peptic ulcer complications has been decreasing in
countries such as Sweden, Norway, and Finland (Ahsberg 2011;
Hermansson 2009; Malmi 2014; Thorsen 2013), hospitalisation
due to peptic ulcer has remained constant from 1996 in the US
(Manuel 2007), while the incidence of complications of peptic
ulcer has remained constant from 1980 in the Netherlands (Post
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2006). Gastric outlet obstruction is another major complication
of peptic ulcer (Barksdale 2002; Zittel 2000), but is not common
in this era of H. pylori eradication and proton pump inhibitor
treatment.
Upper
gastrointestinal endoscopy (oesophageo-gastro-duodenoscopy, or
OGD) is the main method of diagnosis of peptic ulcer. Currently,
OGD is indicated in people with dyspepsia and ’alarm symptoms’
(Ford 2008; Ikenberry 2007). Alarm symptoms include: family
history of upper gastrointestinal malignancy, unintended weight
loss, gastrointestinal bleeding, iron deficiency anaemia, progres-
sive dysphagia (difficulty in swallowing), persistent vomiting, pal-
pable mass or lymphadenopathy, and jaundice (Ikenberry 2007).
In some guidelines, an older age group (ranging from 35 to 55
years, depending upon the geographical region) with new onset
symptoms is an indication for OGD, even in the absence of alarm
symptoms (Ford 2008; Ikenberry 2007). The main purpose of
OGD is to rule out malignancy. While biopsy of gastric ulcers
suspicious of malignancy based on features such as an associated
mass lesion, elevated irregular ulcer borders, and abnormal adja-
cent mucosal folds is recommended, routine biopsy in gastric ul-
cers that are typical of NSAID-associated lesions, that is shallow
flat antral ulcer with associated erosions, may not be necessary, al-
though some malignant ulcers appear benign on endoscopic visu-
alisation initially (ASGE Standards of Practice Committee 2010),
so many endoscopists may perform a routine biopsy of all gastric
ulcers (ASGE Standards of Practice Committee 2010). In addi-
tion to ruling out cancers, biopsies may also be performed to rule
out H. pylori infection (ASGE Standards of Practice Committee
2010). Many endoscopists perform a routine surveillance (follow-
up) endoscopy to ensure that the ulcer has healed and that it is
benign (Breslin 1999). Routine biopsy is not recommended in
duodenal ulcers, since duodenal ulcers are extremely unlikely to be
malignant (ASGE Standards of PracticeCommittee 2010). For the
same reason, routine endoscopic surveillance is not recommended
in duodenal ulcers after resolution of symptoms with treatment
(ASGE Standards of Practice Committee 2010).
Peptic ulcers can be classified in many ways. A simple classification
is between gastric ulcers and duodenal ulcers. This is a clinically
relevant type of classification since the recommendations and en-
doscopists’ preference for biopsy and endoscopic surveillance are
different for gastric ulcers and duodenal ulcers. Various other clas-
sifications of peptic ulcer based on the location and level of acid
secretion have been proposed (Johnson 1965; Vesely 1968), but
none are clinically relevant based on our current understanding of
the important role ofH. pylori on the pathogenesis of peptic ulcers.
A clinically relevant method of classification of peptic ulcer is its
classification into complicated versus uncomplicated peptic ulcer.
Major complications of peptic ulcer include bleeding, perforation,
and gastric outlet obstruction (Barksdale 2002;Hermansson 2009;
Hernandez-Diaz 2013; Malmi 2014; Post 2006; Zittel 2000).
Endoscopic and medical treatments are the mainstay treatment
for acute peptic ulcer bleeding (Lau 2013). Surgery is usually re-
served for unstable patients with recurrent bleeding after endo-
scopic treatment (Beggs 2014;Griffiths 2013). Emergency surgery
in the form of laparoscopic or open repair of the perforated peptic
ulcer is currently the mainstay treatment for perforated peptic ul-
cers (Bertleff 2010). The treatment of patients with gastric outlet
obstruction is more controversial. Elective surgery, which includes
a procedure to allow the food from the stomach to pass into the
small intestine in the form of pyloroplasty or gastrojejunostomy
(drainage procedure), was generally combined with another pro-
cedure to decrease the acid secretion such as truncal vagotomy, se-
lective vagotomy (preserving the hepatic and celiac branches of the
vagus), or highly selective vagotomy (division of gastric branches
of the vagus preserving Latarjet’s nerve to the pylorus) (Barksdale
2002). While endoscopic dilatation of the obstruction is an alter-
native to surgery, the high risk of iatrogenic perforation and high
recurrence rate of peptic ulcer with endoscopic treatment meant
that surgical treatment was preferred over endoscopic treatment
(Barksdale 2002). However, it must be noted that the treatments
for gastric outlet obstruction evolved and were compared before
the era of the pre-proton pump inhibitor andH. pylori eradication.
Description of the intervention
H. pylori eradication achieves ulcer healing rates of more than
90% and is recommended for both gastric and duodenal ul-
cers (Malfertheiner 2012). H. pylori eradication as an empirical
treatment (without confirmation of presence of H. pylori) in re-
gions with high prevalence of H. pylori, and test-and-treat strat-
egy (treatment after confirmation of presence of H. pylori) in re-
gions with low prevalence of H. pylori has been recommended for
the treatment of peptic ulcer (Malfertheiner 2012). The recom-
mended initial treatment is a combination of proton pump in-
hibitor, clarithromycin, and amoxicillin or metronidazole (triple
therapy) in regions with low resistance to clarithromycin (less
than 20% resistance rate in the area) and triple therapy along
with bismuth (quadruple therapy) in regions with high resistance
to clarithromycin (greater than 20% resistance rate in the area)
(Malfertheiner 2012). If this results in failure of eradication, bis-
muth-quadruple therapy or levofloxacin-triple therapy (replace-
ment of clarithromycin with levofloxacin in the classical triple
therapy) when triple therapy was used as the initial treatment
and levofloxacin-triple therapy when bismuth-quadruple therapy
was used as the initial treatment is recommended (Malfertheiner
2012). If even this treatment fails to eradicate H. pylori, then
further treatment should be based on antibiotic susceptibility
(Malfertheiner 2012).
While the requirement for long-term proton pump inhibitors
is low in people with duodenal ulcers, long-term proton pump
inhibitors may be required for those with gastric ulcers (
Malfertheiner 2012). For refractory peptic ulcers (an ulcer that
does not heal after eight to 12 weeks of treatment or one that is
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associated with complications despite treatment), further evalua-
tion of the risk factors and causes of refractory peptic ulcer includ-
ing lifestyle factors such as smoking, alcohol, NSAID use, non-
compliance with medical treatment, gastrinomas (gastrin-secret-
ing tumours), and false-negative H. pylori tests should be carried
out (Napolitano 2009). Further treatment should focus on the
cause of the refractory ulcer, for example smoking or alcohol ces-
sation advice, treatment of resistant H. pylori, high-dose proton
pump inhibitor, or surgical excision of gastrinomas (Napolitano
2009). Various proton pump inhibitors for long-term treatment
of refractory or recurrent ulcer include omeprazole, lansoprazole,
pantoprazole, rabeprazole, and esomeprazole (Katz 2010). Proton
pump inhibitors are generally well tolerated, and adverse effects
are relatively infrequent. The adverse effects reported most often
with proton pump inhibitors are headache, gastrointestinal dis-
turbances, and rash. Occasionally, severe allergic reactions, ana-
phylactic reactions, muscle weakness, reversible confusional states,
mental disturbances, liver failure, kidney damage, and angina have
been reported (Martindale 2011).
Surgery should be considered in patients who are intolerant or
non-compliant with medications, those at high risk for compli-
cations (for example, patients dependent on NSAIDs, ulcers that
fail to heal with adequate medical treatment), and recurrent pep-
tic ulcers despite medical treatment (Napolitano 2009). Surgery
for refractory or recurrent ulcers includes truncal vagotomy and
drainage procedure (pyloroplasty or gastrojejunostomy), selective
vagotomy and drainage, highly selective vagotomy, or partial gas-
trectomy (Napolitano 2009). The complications related to truncal
and selective vagotomy are mortality (less than 0.5%), diarrhoea,
and dumping syndrome, while the major complication associated
with highly selective vagotomy is recurrent peptic ulcers (Lagoo
2014; Napolitano 2009). Vagotomy is usually performed by open
surgery, although case series of laparoscopic vagotomy have been
reported (Palanivelu 2006). Surgery for gastric ulcers usually in-
volves a partial gastrectomy (Napolitano 2009). Partial gastrec-
tomy is usually combined with vagotomy and carries a risk for
mortality (about 1%), as well as diarrhoea and dumping syndrome
(Csendes 2009).
How the intervention might work
Medical treatments such as proton pump inhibitors work by de-
creasing acid secretion (Welage 2003). Since increased acid is con-
sidered to be the cause of ulcer formation, decreasing acid may
result in healing of refractory ulcers and prevention of recurrent
ulcers. Vagotomy is also aimed at decreasing the stimulation of
acid secretion and thus may result in healing of refractory ulcers
and prevention of recurrent ulcers (Napolitano 2009), as the va-
gus nerve controls acid secretion. Truncal vagotomy and selective
vagotomy are combined with drainage procedures (pyloroplasty or
gastrojejunostomy) because of the division of vagal fibres that play
a role in the drainage of food from stomach (Napolitano 2009).
Partial gastrectomy is performed with the intention of decreasing
the amount of acid-secreting cells (Csendes 2009).
Why it is important to do this review
Peptic ulcers cause approximately 3000 to 4500 deaths per year
in the US (Peery 2012; Shaheen 2006). The estimated treatment
costs are between USD 163 and USD 866 per person diagnosed
with peptic ulcer, and the estimated annual costs due to lost pro-
ductivity as a result of peptic ulcer are between USD 943 and
USD 2424 per employed person in the US (Barkun 2010). Over-
all, peptic ulcers cost approximately USD 3.5 billion annually in
treatment costs and lost productivity in the US (Sandler 2002).
Medical management is currently the mainstay treatment for un-
complicated chronic peptic ulcers (Malfertheiner 2011).However,
it should be noted that people with bleeding duodenal ulcers have
a lower prevalence of H. pylori (Malfertheiner 2012). Despite the
treatment of H. pylori, the recurrence rates of bleeding peptic ul-
cers vary between 0% and 37.5% (Lau 2011). Considering that an
acute episode of bleeding results in a short-term mortality of 3%
(Neumann 2013), and that an episode of peptic ulcer perforation
is associated with a short-term mortality of 25% to 30% (Moller
2013), it is important to prevent complications related to recur-
rent or refractory peptic ulcers. Recent concerns about the risk of
fractures with long-term use of proton pump inhibitors mean that
it is not known whether medical or surgical management is the
better treatment option for people with a refractory or recurrent
peptic ulcer (Yu 2011). There have been no systematic reviews
on this issue. This review will provide the best level of evidence
on the comparative benefits and harms of medical versus surgical
management for people with a recurrent or refractory peptic ulcer,
and so allow patients and the healthcare providers involved in their
care to make informed decisions or highlight the lack of evidence
on this topic and provide research recommendations.
O B J E C T I V E S
To assess the benefits and harms of medical versus surgical treat-
ment for people with recurrent or refractory peptic ulcer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
6Medical versus surgical treatment for refractory or recurrent peptic ulcer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We planned to include randomised controlled trials. We planned
to include studies reported as full text, those published as abstract
only, and unpublished data. In the absence of even a single ran-
domised controlled trial, we planned to perform a meta-analysis
of observational studies clearly highlighting the selection bias in
interpreting the results. We anticipated significant selection bias
in observational studies of this comparison since there is a high
possibility that participants with low risk are subject to surgery,
and those at high risk are subject to medical treatment, and the
effect estimates of ameta-analysis of such observational studies can
be misleading. A single randomised controlled trial would have
provided a better estimate of the effect thanmultiple observational
studies (even if they show consistent and precise results) in this
particular situation. Clearly, multiple randomised controlled trials
with consistent effect estimateswould have beenmore reliable than
a single randomised controlled trial. The reason for considering
observational studies was to provide an estimate of the compara-
tive benefits for medical versus surgical management and provide
information for the design of a randomised controlled trial.
Types of participants
We planned to include adults with peptic ulcer irrespective of
whether they are gastric or duodenal ulcers, the priormedical treat-
ment that they received, recurrent or refractory (however defined
by authors, as long as patients had previous medical treatment for
peptic ulcer that had failed), and presence or absence of previous
complications. We planned to exclude patients who previously
underwent surgery for peptic ulcer disease and those who were
unfit for undergoing surgery. We also planned to exclude people
with gastrinomas, for whom surgical removal of gastrinoma is the
treatment of choice.
Types of interventions
We planned to include trials comparing medical versus surgical
treatments for the treatment of peptic ulcer irrespective of the na-
ture of the medical or surgical treatments. We anticipated proton
pump inhibitor to be the medical treatment in most instances.
With regards to surgery, we anticipated vagotomy (with drainage
procedure as appropriate), although studies may include partial
gastrectomy as the surgical treatment.We planned to exclude trials
in which the comparisons solely involved comparison of different
forms of medical treatment or different forms of surgical treat-
ment. We planned to accept co-interventions, for example the use
of lifestyle modification advice, provided they were used equally
in both groups.
Types of outcome measures
Primary outcomes
1. Health-related quality of life (using any validated scale).
i) Short term (four weeks to 12 months).
ii) Medium term (one year to five years).
iii) Long term (> five years).
2. Serious adverse events (within three months of cessation of
treatment; for surgery this period refers to three months after
index surgery). We planned to accept the following definitions of
serious adverse events.
i) International Conference on Harmonisation - Good
Clinical Practice (ICH-GCP) guideline (ICH-GCP 1996):
serious adverse events defined as any untoward medical
occurrence that results in death, is life-threatening, requires
inpatient hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability/
incapacity.
ii) Other variations of ICH-GCP classifications such as
the US Food and Drug Administration (FDA) classification
(FDA 2006), Medicines and Healthcare products Regulatory
Agency (MHRA) classification (MHRA 2013).
Secondary outcomes
1. Adverse events (within three months of cessation of
treatment; for surgery this period refers to three months after
index surgery). We planned to accept all adverse events reported
by the study author irrespective of the severity of the adverse
event.
2. Peptic ulcer bleeding.
i) Short term (four weeks to 12 months).
ii) Medium term (one year to five years).
iii) Long term (> five years).
3. Peptic ulcer perforation.
i) Short term (four weeks to 12 months).
ii) Medium term (four years to five years).
iii) Long term (> five years).
4. Abdominal pain.
i) Short term (four weeks to 12 months).
ii) Medium term (one year to five years).
iii) Long term (> five years).
5. Long-term mortality.
The choice of the above clinical outcomes was to assess the com-
parative safety and clinical improvement in terms of reduced symp-
toms and complications resulting in an improvement in the health-
related quality of life between medical and surgical treatment in
people with peptic ulcers.
Reporting of the outcomes listed here was not an inclusion criteria
for the review.
Search methods for identification of studies
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Electronic searches
We conducted a literature search to identify all published and un-
published randomised controlled trials and non-randomised stud-
ies until September 2015. The literature search identified potential
studies in all languages. We translated the non-English language
papers and fully assessed them for potential inclusion in the review
as necessary.
We searched the following electronic databases to identify poten-
tial studies:
• The specialised register of the Cochrane Upper GI and
Pancreatic Diseases group (September 2015);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Issue 9, 2015) (Appendix 2);
• MEDLINE (1966 to September 2015) (Appendix 3);
• EMBASE (1988 to September 2015) (Appendix 4); and
• Science Citation Index (1982 to September 2015)
(Appendix 5).
We also conducted a search of ClinicalTrials.gov (Appendix 6) and
WHO ICTRP (World Health Organization - International Clin-
ical Trials Registry Platform) on 18 September 2015 (Appendix
7).
Searching other resources
We checked reference lists of the only primary study and review
articles for additional references. We attempted to contact authors
of identified trials to ask them to identify other published and
unpublished studies.
We searched for errata or retractions from eligible trials on http:/
/www.ncbi.nlm.nih.gov/pubmed on 25 November 2015.
Data collection and analysis
Selection of studies
Two review authors (KG and EP) independently screened the ti-
tles and abstracts of all the potential studies we identified as a re-
sult of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We retrieved the full-
text study reports, and two review authors (KG and EP) indepen-
dently screened the full text and identified studies for inclusion
and identified and recorded reasons for exclusion of the ineligible
studies. We resolved any disagreements through discussion. We
identified and excluded duplicates and planned to collate multiple
reports of the same study so that each study rather than each report
was the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table.
Data extraction and management
We planned to use a standard data collection form for study char-
acteristics and outcome data that had been piloted on at least one
study in the review. Two review authors (KG and EP) extracted
study characteristics from included studies. We extracted the fol-
lowing study characteristics.
1. Methods: study design, total duration of study and run in,
number of study centres and location, study setting,
withdrawals, date of study.
2. Participants: number (N), mean age, age range, gender,
gastric ulcer or duodenal ulcer, recurrent or refractory peptic
ulcer, presence or absence of previous peptic ulcer-related
complications, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
interventions.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (KG and EP) independently extracted out-
come data from the included studies. If outcomes were reported
multiple times for the same time frame, for example short-term
health-related quality of life was reported at three months and
12 months, we planned to choose the later time point (that is
12 months) for data extraction. For time-to-event outcomes, we
planned to extract data to calculate the natural logarithm of the
hazard ratio and its standard error using the methods suggested by
Parmar et al (Parmar 1998).
We planned to include all randomised participants for medium-
term outcomes (for example quality of life), and this was not con-
ditional upon the short-term outcomes (for example having a low
or high quality of life index at 12 months).
We planned to note in the ’Characteristics of included studies’
table if outcome data were reported in an unusable way. We re-
solved disagreements by consensus. One review author (KG) en-
tered the data from the data collection form into the ReviewMan-
ager (RevMan) file (Review Manager 2014). We double-checked
that the data were entered correctly by comparing the study re-
ports with how the data were presented in the systematic review.
Assessment of risk of bias in included studies
Two review authors (KG and EP) independently assessed the risk
of bias for each study.We planned to use the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). However, due to the lack of randomised controlled trials
on the topic, we used the relevant ’Risk of bias’ domains from ’A
Cochrane Risk Of Bias Assessment Tool: for Non-Randomized
Studies of Interventions’ (ACROBAT-NRSI) (Sterne 2014).
We assessed the risk of bias according to the following domains:
1. Bias due to confounding
2. Bias due to the selection of participants
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3. Bias due to departures from intended intervention
4. Bias in the measurement of outcomes
5. Bias due to missing data
6. Bias in selection of the reported findings
We resolved any disagreements by discussion.
We graded each potential source of bias as low, moderate, seri-
ous, critical, or no information and have provided a quote from
the study report together with a justification for our judgement
in the ’Risk of bias’ table. We planned to summarise the ’Risk of
bias’ judgements across different studies for each of the domains
listed. We planned to consider bias in the measurement of out-
comes separately for different key outcomes where necessary (for
example for unblinded outcome assessment, risk of bias for all-
cause mortality may be very different than for a patient-reported
health-related quality of life scale). Where information on risk of
bias relates to unpublished data or correspondence with a trialist,
we planned to note this in the ’Risk of bias’ table.
When considering treatment effects, we planned to take into ac-
count the risk of bias for the studies that contribute to that out-
come.
Assessment of bias in conducting the systematic
review
We conducted the review according to this published protocol and
have reported any deviations from it in the Differences between
protocol and review section of the systematic review.
Measures of treatment effect
We planned to analyse dichotomous data as risk ratio and contin-
uous data as mean difference when the outcome was reported in
the same health-related quality of life scale, or standardised mean
difference when different scales were used for measuring quality
of life. We planned to ensure that higher scores for continuous
outcomes have the same meaning for the particular outcome, ex-
plain the direction to the reader, and report where the directions
were reversed if this was necessary. We planned to calculate the
rate ratio for outcomes such as adverse events and serious adverse
events, where it is possible for the same person to develop more
than one adverse event (or serious adverse event). If the authors
had calculated the rate ratio of adverse events (or serious adverse
events) in the intervention versus control based on Poisson regres-
sion, we planned to obtain the rate ratio by the Poisson regression
method in preference to rate ratio calculated based on the num-
ber of adverse events (or serious adverse events) during a certain
period. We planned to calculate the hazard ratio for time-to-event
outcomes such as time to first adverse event (or serious adverse
event).
We planned to undertake meta-analyses only where these were
meaningful, that is if the treatments, participants, and the under-
lying clinical question were similar enough for pooling to make
sense.
A common way that trialists indicate when they have skewed data
is by reporting medians and interquartile ranges. When we en-
countered this, we planned to note that the data were skewed and
to consider the implication of this.
Where multiple trial arms were reported in a single trial, we
planned to include only the relevant arms. If two comparisons
(for example omeprazole versus vagotomy and lansoprazole ver-
sus vagotomy) had to be entered into the same meta-analysis, we
planned to halve the control group to avoid double-counting. The
alternative way of including such trials with multiple arms is to
pool the results of the omeprazole and lansoprazole and compare
it with vagotomy. We planned to perform a sensitivity analysis to
determine if the results of the two methods of dealing with multi-
arm trials led to different conclusions.
Unit of analysis issues
The unit of analysis was the individual participant with refrac-
tory or recurrent peptic ulcer. As anticipated, we did not find any
cluster-randomised trials for this comparison, but if we had iden-
tified cluster-randomised trials, we planned to obtain the effect
estimate adjusted for the clustering effect. If this was not avail-
able, we planned to perform a sensitivity analysis excluding the
trial from the meta-analysis, as the variance of the effect estimate
unadjusted for cluster effect is less than the actual variance which
is adjusted for cluster effect, giving inappropriately more weight
to the cluster-randomised trial in the meta-analysis.
Dealing with missing data
We attempted to contact investigators or study sponsors in order
to verify key study characteristics and to obtain missing numerical
outcome data where possible (for example when a study is identi-
fied as abstract only). If we were unable to obtain the information
from the investigators or study sponsors, we planned to impute the
mean from the median (that is consider median as the mean) and
standard deviation from standard error, interquartile range, or P
values according to the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), but assess the impact of including
such studies as indicated in a sensitivity analysis. If we were unable
to calculate the standard deviation from standard error, interquar-
tile range, or P values, we planned to impute standard deviation
as the highest standard deviation in the remaining trials included
in the outcome, fully aware that this method of imputation would
decrease the weight of the studies in the meta-analysis of mean
difference and shift the effect towards no effect for standardised
mean difference.
Assessment of heterogeneity
We planned to use the I2 statistic to measure heterogeneity among
the trials in each analysis. If we identified substantial heterogene-
ity as per the Cochrane Handbook for Systematic Reviews of Inter-
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ventions (greater than 50% to 60%), we planned to explore it by
prespecified subgroup analysis.
Assessment of reporting biases
We attempted to contact study authors to ask them to provide
missing outcome data. Where this was not possible, and the miss-
ing data were thought to introduce serious bias, we planned to
explore the impact of including such studies in the overall assess-
ment of results by a sensitivity analysis.
If wewere able to poolmore than10 trials, we planned to create and
examine a funnel plot to explore possible publication biases. We
planned to use Egger’s test to determine the statistical significance
of the reporting bias (Egger 1997). We planned to consider a P
value of less than 0.05 as statistically significant reporting bias.
Data synthesis
We planned to perform the analysis using RevMan 5.3 (Review
Manager 2014). We planned to use the Mantel-Haenszel method
for dichotomous data, inverse variance method for continuous
data, and generic inverse variance for count and time-to-event
data. We planned to use both the fixed-effect model and random-
effects model for the analysis (Demets 1987; DerSimonian 1986).
In case of discrepancy between the two models, we planned to
report both results; otherwise we planned to report only the results
from the fixed-effect model.
’Summary of findings’ table
We planned to create a ’Summary of findings’ table using all the
outcomes. We planned to use the five Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) con-
siderations (study limitations, consistency of effect, imprecision,
indirectness, and publication bias) to assess the quality of a body of
evidence as it relates to the studies that contribute data to themeta-
analyses for the prespecified outcomes. We planned to use meth-
ods and recommendations described in Section 8.5 and Chapter
12 of theCochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), and use GRADEpro software. We planned to jus-
tify all decisions to down- or upgrade the quality of studies using
footnotes and make comments to aid the reader’s understanding
of the review where necessary. We planned to consider whether
there was any additional outcome information that could not be
incorporated intometa-analyses and to note this in the comments,
stating if it supports or contradicts the information from themeta-
analyses.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Gastric ulcer versus duodenal ulcer.
2. Recurrent peptic ulcers versus refractory peptic ulcer.
3. Presence versus absence of previous complications
(perforation or bleeding).
4. Different surgery (truncal vagotomy versus selective
vagotomy; pyloroplasty versus gastrojejunostomy).
We planned to use all the primary outcomes in subgroup analysis.
We planned to use the formal Chi2 test for subgroup differences
to test for subgroup interactions.
Sensitivity analysis
We planned to perform the following sensitivity analyses defined
a priori to assess the robustness of our conclusions.
1. Excluding trials at unclear or high risk of bias (one or more
of the ’Risk of bias’ domains (other than blinding of surgeon)
classified as unclear or high).
2. Excluding trials in which either mean or standard deviation
or both were imputed.
3. Excluding cluster-randomised controlled trials in which the
adjusted effect estimates were not reported.
4. Different methods of dealing with multi-arm trials (please
see Measures of treatment effect).
Reaching conclusions
We planned to base our conclusions only on findings from the
quantitative or narrative synthesis of included studies for this re-
view. We have avoided making recommendations for practice, and
our implications for research will provide a clear sense of direction
for any future research in the area and any remaining uncertain-
ties.
R E S U L T S
Description of studies
Results of the search
We identified 11,310 references through electronic searches of
Cochrane (Wiley) (n = 172), MEDLINE (OvidSP) (n = 3032),
EMBASE (OvidSP) (n = 6225), Science Citation Index expanded
(n = 1878), ClinicalTrials.gov (n = 2), and WHO ICTRP (n = 1).
There were 7008 references after removal of duplicate references.
We excluded 6991 clearly irrelevant references through reading ti-
tles and abstracts. We retrieved a total of 17 full-text articles for de-
tailed assessment. We excluded 16 references (15 studies, reports,
or articles) for the reasons listed in Characteristics of excluded
studies. One reference of one non-randomised study fulfilled the
inclusion criteria (see Characteristics of included studies). The
study flow diagram is shown in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
We included only one non-randomised study published 30 years
ago in this review (Adkins 1985). This study included 77 partic-
ipants who had gastric ulcer and in whom medical therapy (his-
tamine H2 receptor blockers, antacids, and diet) had failed after
an average duration of treatment (study authors did not report
whether this was mean or median) of 29 months. The authors
do not state whether these were recurrent or refractory ulcers. Al-
though it was not stated explicitly, we inferred that the participants
did not have previous complications such as bleeding or perfora-
tion.Of the 77 included participants, 37 participants continued to
have medical therapy, while 40 participants received surgical ther-
apy. The surgical therapy included a number of operations such as
antrectomy with or without vagotomy; subtotal gastrectomy with
or without vagotomy; vagotomy; pyloroplasty and suture of the ul-
cer; suture or closure of ulcer without vagotomy or excision of the
ulcer; proximal gastric or parietal cell vagotomy alone; suture or
closure of the ulcer with proximal gastric or parietal cell vagotomy.
The authors state that of the participants in the medical therapy
arm, eight participants received medical therapy because they re-
fused to undergo surgery, and 29 participants were not considered
to be surgical candidates by their gastroenterologists or surgeons.
In addition to the 77 participants who had failed medical treat-
ment, this study also reported on 58 participants who had success-
ful medical treatment and 28 participants who underwent initial
surgical management . The study authors did not report compli-
cations related to medical therapy. They did report complications
related to surgical treatment, but did not report these separately
for participants who underwent surgical treatment for recurrent
or refractory peptic ulcers. They also reported that two partici-
pants in the medical treatment group had gastric cancer (2 out
of 37; 5.4%), which was identified by repeated biopsy. They did
not report the proportion of participants who had gastric cancer
in the surgical treatment group. They also did not report the im-
plications of the delayed diagnosis of gastric cancer in the medical
treatment group. They did not report any of the other outcomes
of interest for this review, thus there was no data to calculate the
effect estimates.
Excluded studies
We excluded five studies because participants had had previous
peptic ulcer surgery (Chung 1998; Kinney 1988; Koo 1982;
Lindenauer 1975; Neustein 1976). We excluded two studies be-
cause they did not evaluate people who had recurrent or refrac-
tory peptic ulcers (Barragry 1986; Mandache 1971). One study
was excluded because people who had failed medical treatment
previously were excluded (Harling 1985). We excluded one study
because there was no separate data on participants who underwent
surgery after recurrent or refractory ulcer (Bardhan 2003). In one
study, all participants receivedmedical treatment after perforation
closure (Brehant 2008), and another study reported only on par-
ticipants who received medical treatment and underwent emer-
gency surgery because of catastrophic bleeding (Bouillot 1991);
there were no comparator groups in these two studies. We ex-
cluded four reports because they were reviews or letters to editor
(Amdrup 1981; Anonymous 1981; De Vernejoul 1947; Nguyen
2007).
Risk of bias in included studies
Bias due to confounding
The risk of bias due to confounding was unclear in the only study
included in this review, as baseline characteristics were not re-
ported (Adkins 1985). We therefore classified this domain as ’No
information’.
Bias due to the selection of participants
The only study included in this review reported that the reason
for participants receiving medical treatment was because of par-
ticipant’s or physician’s preference (Adkins 1985). As this might
have introduced bias, we have classified this domain as ’critical’
risk of bias.
Bias due to departures from intended intervention
The only study included in this review did not report whether the
patient care other than medical or surgical treatment was identi-
cal in the two groups (Adkins 1985). We therefore classified this
domain as ’No information’.
Bias in the measurement of outcomes
The only study included in this review did not report whether
the outcome assessors were blinded (Adkins 1985). We therefore
classified this domain as ’No information’.
Bias due to missing data
All participants with gastric ulcers who failed medical treatment
were included in the only study included in this review (Adkins
1985), therefore this domain was classified as ’low’ risk of bias.
Bias in selection of the reported findings
The only study included in this review did not adequately report
on any of the outcomes that can be expected to be reported in a
study of this nature, such as mortality and complications. (Adkins
1985). We therefore classified this domain as ’critical’ risk of bias.
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Effects of interventions
See: Summary of findings for the main comparison Medical
treatments compared with surgery for refractory or recurrent
peptic ulcer
The only study included in this review did not report any of the
outcomes of interest for this review (Adkins 1985). The study
authors reported that two participants in the medical treatment
group (2 out of 37; 5.4%) had gastric cancer, which was identified
by repeated biopsy. They did not report the proportion of par-
ticipants who had gastric cancer in the surgical treatment group.
They also did not report the implications of the delayed diagnosis
of gastric cancer in the medical treatment group.
Since the study did not report data that could be analysed, we
could not perform any of the planned analyses.
D I S C U S S I O N
Summary of main results
We included only one non-randomised study published 30 years
ago in this review (Adkins 1985). This study included 77 partic-
ipants who had gastric ulcer and in whom medical therapy (his-
tamine H2 receptor blockers, antacids, and diet) had failed after
an average treatment duration of 29 months. The study authors
reported that two participants in the medical treatment group (2
out of 37; 5.4%) had gastric cancer, which was identified by re-
peated biopsy. They did not report the proportion of participants
who had gastric cancer in the surgical treatment group. They also
did not report the implications of the delayed diagnosis of gastric
cancer in the medical treatment group. They did not report any
other outcomes of interest.
Overall completeness and applicability of
evidence
The only study included in this review was published 30 years
ago. The medical treatment used in this study was histamine H2
receptor blockers and antacid. As the current recommended treat-
ment for peptic ulcers is proton pump inhibitors, the results of the
study are not applicable to the current situation. In the absence
of any evidence from randomised or non-randomised studies, we
have discussed the major issues that must be considered when de-
ciding whether a person undergoes medical or surgical treatment
for recurrent or refractory peptic ulcer.
The first issue is gastric cancer in refractory gastric ulcers. Gas-
tric cancer can present as gastric ulcer, sometimes without the
typical characteristics of a malignant gastric ulcer such as associ-
ated mass lesion, elevated irregular ulcer borders, and abnormal
adjacent mucosal folds. The sensitivity of endoscopy for detect-
ing malignancy is approximately 72% to 95% (Bustamante 2002;
Gielisse 2015; Manas 2009), so many endoscopists may perform
a routine biopsy of all gastric ulcers (ASGE Standards of Practice
Committee 2010). Follow-up endoscopy examination of patients
with a previous negative endoscopic biopsy revealed that approx-
imately 0.9% to 4.5% of patients have gastric cancer despite an
initial negative endoscopic biopsy (Eckardt 1992; Hopper 2006;
Hosokawa 2001). A recent study showed that none of the par-
ticipants with a previous negative endoscopic biopsy had gastric
cancer (Gielisse 2015), that is a single endoscopy with biopsy
had a 100% sensitivity in detecting gastric cancer in gastric ulcer.
However, these excellent results have not been replicated in other
studies as mentioned above. Treatment of gastric cancer may be
delayed because of the misdiagnosis of malignant gastric ulcer as
peptic ulcer (Podolsky 1988). In addition, approximately 1.6%
(1470 out of 92,250) of patients with pre-malignant lesions with
atrophic gastritis, intestinal metaplasia, and dysplasia developed
gastric cancer (de Vries 2008). Most of these cancers developed in
people with severe dysplasia (de Vries 2008). Routine surgery for
refractory or recurrent gastric ulcers will result in earlier treatment
of gastric cancers and avoid the risk of pre-malignant lesions turn-
ing malignant. However, this exposes the patients to the compli-
cations of partial gastrectomy, which carries a risk for mortality
(about 1%), as well as diarrhoea and dumping syndrome (Csendes
2009).
Othermajor factors that must be considered in addition to the risk
of malignancy in gastric ulcers are the risk of bleeding and perfora-
tion in people who are treated medically and surgically for recur-
rent or refractory peptic ulcer, as mentioned in the Background, as
well as health-related quality of life and loss of productivity after
medical and surgical treatment.
With the increasing role of bariatric surgery in obese people (NICE
2014), the issue about medical versus surgical treatment of re-
fractory or recurrent peptic ulcers may become an important is-
sue in this population, as 0.6% to 25% of people who undergo
Roux-en-Y gastric bypass surgery (a common bariatric surgery)
develop peptic ulcers (Coblijn 2014; Edholm 2015). These are
called ’marginal ulcers’, ’ischaemic ulcers’, or ’anastomotic ulcers’
(Coblijn 2014). While about two-thirds of marginal ulcers can be
treated medically, the remaining ones need endoscopic or surgi-
cal treatment, mostly in the form of revisional surgery (Coblijn
2014). Vagotomy has been proposed as an alternative for revisional
surgery for people with refractory marginal ulcers (Hunter 2012).
Given the number of deaths and the socioeconomic importance of
peptic ulcer (which might increase with the growing popularity of
bariatric surgery), it is important to determine the relative benefits
and harms of medical versus surgical treatment for people with
refractory or recurrent peptic ulcers.
Quality of the evidence
The only study that was included in this review had unclear risk
of bias in most domains and critical risk of bias in bias due to
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confounding and selective outcome reporting. This study did not
report any outcome of interest, therefore the quality of evidence
could not be formally determined using GRADE methodology.
Potential biases in the review process
We planned to include randomised controlled trials only if at least
one randomised controlled trial was available for this review. How-
ever, in the absence of any randomised controlled trials, we have
reported the best available evidence on the topic. We removed
the randomised controlled trial filter to ensure that observational
studies were not removed by the electronic filters. Two review au-
thors independently selected studies without using any language
restrictions and extracted data, decreasing the likelihood of poten-
tial errors in study selection and data extraction. However, this is a
systematic review of non-randomised studies. There is no require-
ment for mandatory registration, and many studies may not have
been submitted to the journals by study authors, particularly if the
morbidity related to peptic ulcers was high. We therefore cannot
rule out publication bias.
Agreements and disagreements with other
studies or reviews
This is the first systematic review on the topic. We are unable
to recommend a definitive treatment algorithm as suggested by
Napolitano et al because of the paucity of information (Napolitano
2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no study that provides the relative benefits and harms of
medical versus surgical treatment for recurrent or refractory peptic
ulcers.
Implications for research
Studies that evaluate the natural history of recurrent and refrac-
tory peptic ulcers are urgently required to determine whether ran-
domised controlled trials comparing medical versus surgical man-
agement in patients with recurrent or refractory peptic ulcers or
both are necessary. Such studies will also provide information for
the design of such randomised controlled trials. The initial medi-
cal management should include proton pump inhibitors as a min-
imum and may consider H. pylori eradication therapy, particularly
in areas of high prevalence of H. pylori, before concluding that
a peptic ulcer is recurrent or refractory. Participants should also
be screened and treated for gastrinomas prior to classifying them
as recurrent or refractory ulcers. The medical treatment of recur-
rent and refractory peptic ulcers should include proton pump in-
hibitors. Aminimum follow-up of two to three years will allow the
calculation of the incidence of complications and gastric cancer
(in gastric ulcers only) in recurrent and refractory peptic ulcers. In
addition to complications related to treatment and disease, health-
related quality of life and loss of productivity should also be mea-
sured.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adkins 1985
Methods Retrospective cohort study
Participants Country: USA
Number included: 77
Number of eligible people excluded: 0 (0%)
Revised sample size: 77
Average age: not stated
Gender: not stated
Gastric ulcer: 77 (100%)
Duodenal ulcer: not stated
Recurrent peptic ulcer: not stated
Refractory peptic ulcer: not stated
Presence of previous peptic ulcer-related complications: none (not stated explicitly in
the study but can be inferred)
Inclusion criteria
People with gastric ulcer who failed medical therapy after histamine H2 receptor block-
ers, antacids, and diet (average duration (mean or median - not stated) of medical treat-
ment: 29 months)
Interventions Group 1: medical treatment (n = 37)
Further details: histamine H2 receptor blockers, antacids, and diet
Group 2: surgical treatment (n = 40)
Further details: several operation types
Outcomes None of the outcomes of interest were reported adequately
Notes 2 participants in the medical treatment group had gastric cancer, which was identified
by repeated biopsy
Risk of bias
Bias Authors’ judgement Support for judgement
Bias due to confounding Unclear risk No information
Comment: Authors do not provide baseline characteristics
between those who continued medical treatment and who
underwent surgery
Bias due to selection of participants to in-
tervention and control
High risk Critical risk of bias
Quote: “Eight of these 37 have refused surgical treatment,
and 29 for some reason apparently have not been consid-
ered to be surgical candidates by their gastroenterologists
and/or by their surgeons”
Comment: This could have introduced selection bias
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Adkins 1985 (Continued)
Bias due to differences in co-interventions
which were different between the groups
Unclear risk No information
Comment: This information was not available
Bias in the measurement of outcomes Unclear risk No information
Comment: This information was not available
Bias due to missing data Low risk Low risk of bias
Comment: All participants with gastric ulcers during the
period were included in the report
Bias in selection of the reported findings High risk Critical risk of bias
Comment: None of the outcomes that can be expected to
be reported in a study of this nature such as mortality and
complications were reported adequately
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Amdrup 1981 Review
Anonymous 1981 Review
Bardhan 2003 No separate data on participants who underwent surgery after refractory ulcer
Barragry 1986 Did not evaluate recurrent or refractory ulcers
Bouillot 1991 Participants received medical treatment, and all underwent emergency surgery due to catastrophic bleeding
Brehant 2008 All participants received medical treatment after perforation closure
Chung 1998 Participants had had previous surgery for peptic ulcer disease
De Vernejoul 1947 Letter to editor
Harling 1985 People who had failed earlier treatment with cimetidine were excluded
Kinney 1988 Participants had had previous surgery for peptic ulcer disease
Koo 1982 Participants had had previous surgery for peptic ulcer disease
Lindenauer 1975 Participants had had previous surgery for peptic ulcer disease
Mandache 1971 Did not evaluate recurrent or refractory ulcers
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(Continued)
Neustein 1976 Participants had had previous surgery for peptic ulcer disease
Nguyen 2007 Review
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Glossary of terms
Adjacent: nearby.
Anaphylactic shock: life-threatening allergic reaction characterised by breathing difficulties or very low blood pressure or both.
Antral ulcers: ulcers in the antrum, the lower part of the stomach.
Antrectomy: removal of antrum, the lower part of the stomach.
Benign: non-cancerous (in this context).
Bismuth: anti-ulcer drug.
Clarithromycin, amoxicillin, metronidazole: antibiotics
Diarrhoea: frequent and loose stools
Dumping syndrome: feeling of fullness after a small meal, abdominal pain, light-headedness, and urgent requirement to pass stools.
Duodenum: first part of small intestine.
Dyspepsia: indigestion resulting in fullness, bloating, early satiety, and nausea.
Eradication: destruction.
Erosions: break only in the mucosa without a break in the deeper layers (in this context).
Endoscopy: the insertion of a tube with a camera and light through the mouth (in this context) to allow visual examination of the
oesophagus (food pipe), stomach, and the upper part of the small intestine.
Gastrectomy: removal of complete stomach or part of stomach.
Gastric outlet obstruction: obstruction to the flow of food from the stomach into the small bowel.
Gastric: stomach.
Gastric mucosa: mucosa (inner lining) of the stomach.
Gastrin: hormone that increases secretion of acid in the stomach. This hormone is secreted by the gastric mucosa (inner lining of the
stomach).
Gastrointestinal: digestive.
Gastrojejunostomy: creating a connection between stomach and the jejunum, the second part of the small intestine.
Helicobacter pylori (H. pylori): a bacterium found usually in the stomach that is believed to be the cause of a number of diseases,
including stomach ulcers and stomach cancer.
Highly selective vagotomy: division of the branches of the vagus nerve that control the acid secretion without dividing the nerve
branches that control the valve-like mechanism that allows food to pass from the stomach into the small bowel.
Histamine H2 receptor blockers: medicines that block the action of a chemical called histamine resulting in a decreased production of
stomach acid. Histamine stimulates the stomach cells to secrete stomach acid.
Iatrogenic: accidental or unintentional complication caused by a medical examination or treatment.
Iron deficiency anaemia: an abnormal decrease in red blood cells caused by low iron levels in the blood.
Jaundice: yellowish discolouration of skin and white of the eye and dark urine resulting from accumulation of bile pigments (waste
products normally excreted in bile).
Lymphadenopathy: enlarged lymph glands or lymph nodes.
Malignant: cancer (in this context).
Mass: lump (in this context).
Metaplasia: replacement of cell type with another cell type that is native to another site within the body or transformation of one tissue
into another.
Mucosa: inner lining of food pipe, stomach, and bowel.
Pathogenesis: mechanism of how a disease or a complication is caused.
Person-years: equivalent to 1000 persons at risk of developing peptic ulcer followed for one year or 500 persons at risk of developing
peptic ulcer followed for two years, and so on.
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Proton pump inhibitor: proton pump is the pump that is responsible for secreting acid by the stomach cells. Proton pump inhibitors
are drugs that decrease the secretion of acid by blocking these pumps.
Pyloroplasty: widen the opening in the lower part of the stomach.
Pylorus: the lower end of the stomach, which is controlled by a valve-like mechanism that allows food to pass from the stomach into
the small bowel.
Satiety: the feeling of having eaten enough or too much.
Selective vagotomy: division of branches of the vagus that supply the stomach without dividing those supplying the liver.
Truncal vagotomy: division of the abdominal vagus nerve trunks, which control acid secretion and the movement of the intestines.
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor: [Stomach] explode all trees
#2 stomach or gastr*
#3 MeSH descriptor: [Duodenum] explode all trees
#4 duoden*
#5 peptic*
#6 MeSH descriptor: [Esophagus] explode all trees
#7 esophag* or oesophag*
#8 MeSH descriptor: [Peptic Ulcer] explode all trees
#9 (peptic adj5 ulcer*) or (stomach adj5 ulcer*) or (duoden* adj5 ulcer*) or (gastroduoden* adj5 ulcer*)
#10 #1 or #2 or #3 or #4 or #5 or #5 or #6 or #7 or #8 or #9
#11 (recurrent or refractory or non-healing or fail*)
#12 MeSH descriptor: [Gastrectomy] explode all trees
#13 gastrectomy
#14 MeSH descriptor: [Vagotomy] explode all trees
#15 vagotomy
#16 (pyloroplasty or gastrojejunostomy or antrectomy or antrum resection or antral resection)
#17 #12 or #13 or #14 or #15 or #16
#18 #10 and #11 and #17










10. exp peptic ulcer/
11. (peptic adj5 ulcer*).mp.
12. (stomach adj5 ulcer*).mp.
13. (duoden* adj5 ulcer*).mp.
14. (gastroduoden* adj5 ulcer*).mp.
15. or/1-14
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22. gastrojejunostomy.tw.
23. (antrectomy or antrum resection or antral resection).mp.
24. or/17-23
25. 15 and 16 and 24
26. exp animals/ not humans.sh.
27. 25 not 26










10. exp peptic ulcer/
11. (peptic adj5 ulcer*).mp.
12. (stomach adj5 ulcer*).mp.
13. (duoden* adj5 ulcer*).mp.
14. (gastroduoden* adj5 ulcer*).mp.
15. or/1-14









25. exp stomach antrum resection/
26. (antrectomy or antrum resection or antral resection).mp.
27. or/17-26
28. 15 and 16 and 27
Appendix 5. Science Citation Index search strategy
# 1 TS= (stomach or gastr* or duoden* or peptic* or esophag* or oesophag* or (peptic and ulcer*) or (stomach and ulcer*) or (duoden*
and ulcer*) or (gastroduoden* and ulcer*)
# 2 TS= (recurrent or refractory or non-healing or fail*)
# 3 TS= (gastrectomy or vagotomy or pyloroplasty or gastrojejunostomy or antrectomy or antrum resection or antral resection)
# 4 #1 AND #2 AND #3
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Appendix 6. ClinicalTrials.gov search strategy
“Interventional” [STUDY-TYPES] AND ( “Phase 2” OR “Phase 3” OR “Phase 4” ) [PHASE] | “peptic ulcer” OR “duodenal ulcer”
OR “gastric ulcer” | gastrectomy OR vagotomy OR pyloroplasty OR gastrojejunostomy OR antrectomy OR “antrum resection” OR
“antral resection”
Appendix 7. WHO ICTRP search strategy
Title: gastrectomy or vagotomy or pyloroplasty or gastrojejunostomy or antrectomy or antrum resection or antral resection
Condition: peptic ulcer or gastric ulcer or duodenal ulcer
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since we identified no randomised controlled trials, we included non-randomised studies in order to provide the best currently available
evidence. As a result, we made the following modifications to the protocol.
1. We did not use the filter for randomised controlled trials for the electronic searches of the databases.
2. We used ’A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions’ (ACROBAT-NRSI) tool
for assessment of risk of bias rather than the standard Cochrane ’Risk of bias’ tool for randomised controlled trials.
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